Share this article
Share this article
NEW YORK, June 1, 2021 /PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ( Omeros or the Company ) (NASDAQ: OMER). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether Omeros and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On May 20, 2021, Omeros issued a press release report[ing] that the U.S. Food and Drug Administration (FDA) will require additional time to review the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Omeros advised investors that [t]he new Prescription Drug User Fee Act (PDUFA) target action date is October 17, 2021.
/PRNewswire/ CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2021. "The U.S. Food and Drug.
CTI BioPharma: FDA Accepts NDA For Pacritinib As Treatment For Myelofibrosis Patient
WASHINGTON (dpa-AFX) - CTI BioPharma Corp. (CTIC) said Tuesday that the U.S. Food and Drug Administration has accepted its New Drug Application or NDA for pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia, with the NDA being granted Priority Review.
The Prescription Drug User Fee Act (PDUFA) target action date is November 30, 2021.
The FDA is not currently planning to hold an advisory committee meeting to discuss the NDA.
With commercial preparation underway, the company believes it will be well positioned for a potential U.S. launch later this year.
FINAL DEADLINE ALERT: ROSEN, LEADING AND LONGSTANDING INVESTOR COUNSEL, Encourages Kadmon Holdings, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important June 2 Deadline in Securities Class Action – KDMN The Rosen Law Firm PA New York, New York, UNITED STATES
NEW YORK,, May 27, 2021 (GLOBE NEWSWIRE)
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kadmon Holdings, Inc. (NASDAQ: KDMN) between October 1, 2020 and March 10, 2021, inclusive (the “Class Period”) of the important June 2, 2021 lead plaintiff deadline.
SO WHAT: If you purchased Kadmon securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.